HAVN Life Sciences Inc.
HAVLF · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $517 | $753 | $222 | $9,210 |
| - Cash | $14 | $9 | $112 | $1,056 |
| + Debt | $26 | $310 | $562 | $389 |
| Enterprise Value | $529 | $1,054 | $671 | $8,544 |
| Revenue | -$12 | $315 | $68 | $216 |
| % Growth | -103.8% | 363.5% | -68.6% | – |
| Gross Profit | -$83 | $202 | $22 | $68 |
| % Margin | 690.9% | 64.1% | 32.4% | 31.5% |
| EBITDA | -$691 | -$603 | -$906 | -$11,186 |
| % Margin | 5,733.3% | -191.7% | -1,334.3% | -5,169.6% |
| Net Income | -$692 | -$2,479 | -$3,903 | -$11,367 |
| % Margin | 5,734.1% | -787.5% | -5,747.4% | -5,253.1% |
| EPS Diluted | -0.071 | -0.41 | -27.05 | -2.38 |
| % Growth | 82.6% | 98.5% | -1,036.6% | – |
| Operating Cash Flow | $289 | -$558 | -$891 | -$1,450 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $289 | -$558 | -$891 | -$1,450 |